-
@CADTH_ACMTS
Devastating that Lorlatinib & Atezolizumab (For ALK+ and SCLC #LungCancer ) were not approved by HTA funding $$$$, despite strong evidence that shows OS. We Deserve to access to Life extending Meds.#WeDeserveToLive#LCSM#LCAM http://bit.ly/2uXiVVm pic.twitter.com/pBjFVyKXrI
Prikaži ovu nit -
The safety profile of the combination was consistent with prior trials and the current label for dinutuximab
#lcam#lcsmhttp://ow.ly/3Nb250ycyRW -
.
@benlevylungdoc of@hopkinskimmel discusses the next steps with liquid biopsies in#NSCLC and its broader use in oncology#lcsm#lcam http://ow.ly/xtaW50ycztH -
The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory
#SCLC, missing the primary endpoint of the phase II/III DISTINCT trial#lcsm#lcam http://ow.ly/S9tA50ycyRp -
Immune checkpoint inhibitors have yielded modest improvement in
#SCLC, but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches#lcsm#lcam http://ow.ly/xA5F50ycyxF -
Neural "Fingerprint" Enables Personalized SBRT Dose for Lung Cancer
#lcam#lcsmhttp://ow.ly/idCM50y8v7P -
FDA Approvals Boost Competition in Treatment Landscapes
#lcsm#lcam http://ow.ly/sdOs50y8uRX -
NICE Recommends Against Frontline Osimertinib in EGFR-Mutant
#NSCLC#lcsm#lcam http://ow.ly/9nmM50y8uQu -
"Ultrathin" Bronchoscopy Improves Care for Patients With Lung Nodules
#lcsm#lcam http://ow.ly/MMTh50y8uPS -
FDA Grants Priority Review to Selpercatinib for RET Fusion+
#NSCLC and Thyroid Cancers#lcsm#lcam http://ow.ly/SxWC50y8uOe -
Standardizing biomarker testing for Canadian patients with advanced
#lungcancer#LCAM#LCSM https://current-oncology.com/index.php/oncology/article/view/3867/2634#.XjWLH7OKLMo.twitter … -
Shockingly
#1Killer in Cancers#LungCancer Still Most Commonly Diagnosed in Emergency Admissions , this needs to Change#LCAM#LCSM https://www.medscape.com/viewarticle/924597?src=soc_tw_share … via@medscape -
All you NEED is LUNGS : There's a lung cancer stigma, and it's making people sick
#lcam#lcsm https://www.yahoo.com/lifestyle/nobody-deserves-cancer-theres-a-lung-cancer-stigma-and-its-making-people-sick-002849994.html?soc_src=social-sh&soc_trk=tw … via@YahooLifestyle -
#LungCancer Early diagnosis is critical to improved#survivorship and#screening is key. Comprehensive low-dose CT screening programs would change this#1Killer Cancer Stats#LDCT#ResearchMatters#morefunding#changeLungCancer#WeDeservetoLive#LCAM#LCSMpic.twitter.com/x1j84EcZNE
-
The FDA has scheduled an Oncology Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection
#lcsm#lcam http://ow.ly/KVP150y8um4 -
The 2020 VAPALS Summit kicks off in Atlanta on January 30 to bring together approximately 100 clinicians from 20 VA medical centers to discuss implementation strategies to reduce lung cancer mortality among Veterans with early detection annual low dose chest CT scans.
#lcam pic.twitter.com/dmGlj6T7Fv
-
The
@FDAOncology Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+#NSCLC#lcsm#lcam http://ow.ly/3djW50y8ugT -
Meanwhile #433 die each day from
#LungCancer#LCAM Coronavirus terrifies us, but another virus has already killed 6,000 in US https://www.burlingtoncountytimes.com/zz/news/20200124/coronavirus-terrifies-us-but-another-virus-has-already-killed-6000-in-us … -
We spoke with
@LeciaSequist and@ZPiotrowskaMD of@MGHCancerCenter about remaining questions in immunotherapy and targeted therapy for advanced#NSCLC in this week's#OncLiveOnAir#lcsm#lcam http://ow.ly/GAFV50y8dZQ pic.twitter.com/oipwfhOkJE
-
The 2020 VAPALS Summit gives special thanks to Dr. Haval Balata who is traveling from Manchester, UK to deliver our Keynote Lecture. The
@NHSuk program that he will discuss offers a model that appears feasible for#VA.#lcam#lcsmpic.twitter.com/BT6qCz1eNf
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.